Silicone based membranes for use in implantable glucose sensors
Membrane systems incorporating silicone polymers are described for use in implantable analyte sensors. Some layers of the membrane system may comprise a blend of a silicone polymer with a hydrophilic polymer, for example, a triblock poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) polymer. Such polymeric blends provide for both high oxygen solubility and aqueous analyte solubility.
1. A transcutaneous implantable continuous analyte sensor, comprising:
a working electrode configured to be transcutaneously implanted; and
a membrane disposed over at least a portion of the working electrode, the membrane comprising a blend, the blend comprising a silicone-containing polymer and a hydrophilic polymer;
wherein the membrane is configured to reduce or block passage therethrough of acetaminophen, whereby when:
(1) the sensor is placed in a 2L bath filled with phosphate buffered saline, continuously stirred, brought to a temperature of 37° C., allowed to equilibrate for 1 hour until the sensor reaches a flat line continuous baseline signal; and
(2) acetaminophen is then added to the bath to a dilution of 3.8 mg/dL and the sensor is then allowed to equilibrate over 1 hour while measurements are continuously recorded from the sensor;
the signal does not change by more than 1%.
2. The implantable continuous analyte sensor of claim 1 , wherein the silicone-containing polymer is cross-linked with the hydrophilic polymer.
3. The implantable continuous analyte sensor of claim 1 , wherein the hydrophilic polymer has a molecular weight of at least about 1,000 g/mol.
4. The implantable continuous analyte sensor of claim 1 , wherein the hydrophilic polymer has a molecular weight of at least about 10,000 g/mol.
5. The implantable continuous analyte sensor of claim 1 , wherein the hydrophilic polymer has a molecular weight of at least about 15,000 g/mol.
6. The implantable continuous analyte sensor of claim 1 , wherein up to 25% of the silicone-containing polymer is covalently linked to the hydrophilic polymer.
7. The implantable continuous analyte sensor of claim 1 , wherein up to 15% of the silicone-containing polymer is covalently linked to the hydrophilic polymer.
8. The implantable continuous analyte sensor of claim 1 , wherein up to 5% of the silicone-containing polymer is covalently linked to the hydrophilic polymer.
9. The implantable continuous analyte sensor of claim 1 , wherein the hydrophilic polymer comprises a material selected from the group consisting of polyvinylpyrrolidone, polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers, and copolymers thereof.
10. The implantable continuous analyte sensor of claim 1 , wherein the membrane is configured to inhibit transport of an interfering species therethrough.
11. The implantable continuous analyte sensor of claim 1 , wherein the membrane is configured to reduce a flux of an analyte therethrough.
12. The implantable continuous analyte sensor of claim 1 , wherein the membrane comprises an enzyme configured to react with an analyte.
13. The implantable continuous analyte sensor of claim 1 , wherein the membrane further comprises a polyanionic polymer.
14. A transcutaneous implantable continuous analyte sensor, comprising:
a working electrode configured to be transcutaneously implanted; and
a membrane disposed over the working electrode, the membrane comprising:
a first domain comprising a blend of a silicone-containing polymer and a hydrophilic polymer, the first domain configured to reduce permeability of acetaminophen;
a second domain comprising an enzyme configured to react with an analyte; and
a third domain comprising ionic components configured to reduce permeability of the third domain to an interfering species;
wherein the first domain is configured to reduce or block passage therethrough of acetaminophen, whereby when:
(1) the sensor is placed in a 2L bath filled with phosphate buffered saline, continuously stirred, brought to a temperature of 37° C., allowed to equilibrate for 1 hour until the sensor reaches a flat line continuous baseline signal; and
(2) acetaminophen is then added to the bath to a dilution of 3.8 mg/dL and the sensor is then allowed to equilibrate over 1 hour while measurements are continuously recorded from the sensor;
the signal does not change by more than 1%.
15. The implantable continuous analyte sensor of claim 14 , wherein the first domain is positioned more distal to the working electrode than the second domain, and wherein the second domain is positioned more distal to the working electrode than the third domain.
16. The implantable continuous analyte sensor of claim 14 , wherein the hydrophilic polymer comprises a material selected from the group consisting of polyvinylpyrrolidone, polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers, and copolymers thereof.